Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
L Bonello, US Tantry, R Marcucci, R Blindt… - Journal of the American …, 2010 - jacc.org
The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives
DJ Angiolillo, A Fernandez-Ortiz, E Bernardo… - Journal of the American …, 2007 - jacc.org
Antiplatelet therapy is the cornerstone of treatment for patients with acute coronary
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …
syndromes and/or undergoing percutaneous coronary interventions. Clopidogrel, in …
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
AR Shuldiner, JR O'Connell, KP Bliden, A Gandhi… - Jama, 2009 - jamanetwork.com
Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …
coronary syndromes and following percutaneous coronary intervention by inhibiting …
[HTML][HTML] A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
Background: Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active
metabolite. The clinical significance of this drug interaction is unknown. Methods: We …
metabolite. The clinical significance of this drug interaction is unknown. Methods: We …
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
S Matetzky, B Shenkman, V Guetta, M Shechter… - Circulation, 2004 - Am Heart Assoc
Background—Although clopidogrel reduces the risk of cardiovascular episodes after
coronary events and stenting, a substantial number of incidents continue to occur. Methods …
coronary events and stenting, a substantial number of incidents continue to occur. Methods …
Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study
Objectives: This trial sought to assess the influence of omeprazole on clopidogrel efficacy.
Background: Clopidogrel has proved its benefit in the treatment of atherothrombotic …
Background: Clopidogrel has proved its benefit in the treatment of atherothrombotic …
The role of genetic polymorphism and other factors on clopidogrel resistance (CR) in an Asian population with coronary heart disease (CHD)
Clopidogrel is a widely-used antiplatelet drug. It is important for the treatment and prevention
of coronary heart disease. Clopidogrel can effectively reduce platelet activity and therefore …
of coronary heart disease. Clopidogrel can effectively reduce platelet activity and therefore …
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
The capacity of clopidogrel to inhibit ADP-induced platelet aggregation shows wide
intersubject variability. To determine whether frequent functional variants of genes coding for …
intersubject variability. To determine whether frequent functional variants of genes coding for …
Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents
M Pfisterer, HP Brunner-La Rocca, PT Buser… - Journal of the american …, 2006 - jacc.org
Objectives: We sought to define the incidence of late clinical events and late stent
thrombosis in patients treated with drug-eluting (DES) versus bare-metal stents (BMS) after …
thrombosis in patients treated with drug-eluting (DES) versus bare-metal stents (BMS) after …